AMENDMENTS TO THE CLAIMS

Please cancel claims 107-142, without prejudice or disclaimer, so that the pending claims are as follows:

1-79. (Canceled).

80. (Previously presented) A sustained-release dosage form, comprising oxymorphone or a salt thereof, a hydrophilic polymer, a binder, and a diluent.

81. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form contains granules having a diameter from about 0.1 mm to about 3 mm.

82. (Previously presented) The sustained-release dosage form of claim 80, further comprising an alkylcellulose.

83. (Previously presented) The sustained-release dosage form of claim 80, further comprising ethylcellulose.

84. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a tablet.

85. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a capsule.

86. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a matrix.

87. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

88. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

89. (Previously presented) A sustained-release dosage form, made by the process comprising: (a) mixing oxymorpbone or a salt thereof with a hyrodrophilic polymer, a binder, and a diluent; (b) subjecting the mixture to shear to form granules; and (c) incorporating the granules into a dosage form.

90. (Previously presented) The process of claim 89, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

91. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a tablet.

92. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a capsule.

93. (Previously presented) The process of claim 89, wherein the dosage form is a matrix.

94. (Previously presented) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with an alkylcellulose.

95. (Previously presented) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

96. (Previously presented) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

97. (Previously presented) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

98. (Previously presented) A process of making a sustained-release dosage form comprising: (a) mixing oxymorphone or a salt thereof with a hydrophilic polymer, a binder, and a diluent: (b) subjecting the mixture to shear to form granules; and (c) incorporating the granules into a dosage form.

99. (Previously presented) The process of claim 98, wherein the granules have a diameter from about 0.1 mm to about 3mm.

100. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a tablet.

101. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a capsule.

102. (Previously presented) The process of claim 98, wherein the dosage form is a matrix.

103. (Previously presented) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with alkylcellulose.

104. (Previously presented) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

105. (Previously presented) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

106. (Previously presented) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

107-142. (Canceled).

* * * * *